Prestige Consumer Healthcare → LaCorium Health
completedUS consumer health company Prestige Consumer Healthcare bought Australian therapeutic skincare business LaCorium Health (Dermal Therapy, Flexitol, Crampeze) for about US$150m (~A$225m), completing the deal in July 2026.
Prestige wanted an established, profitable Australian brand portfolio (~$40m revenue, ~$12m EBITDA post-synergies) it could plug straight into its existing distribution rather than build a local skincare brand from nothing.
For LaCorium's owners, folding into a larger consumer health group gave the brands more shelf space and marketing muscle than they'd get as an independent Australian business.
No specific Prestige Consumer Healthcare (NYSE: PBH) share price reaction was reported in available coverage. LaCorium is privately held, so it has no public share price.
Framed as a bolt-on brand acquisition rather than a transformative deal — small relative to Prestige's balance sheet, aimed at plugging an established, profitable niche portfolio into existing distribution.
Deal mechanics
Not publicly disclosed
Not publicly disclosed
All-cash acquisition for approximately US$150m
About 12.5x EV/EBITDA and 3.75x EV/revenue, calculated from LaCorium's disclosed ~$40m revenue and ~$12m post-synergy EBITDA
Not publicly disclosed; likely required FIRB approval given LaCorium is an Australian target
A $95m add-on term loan plus cash on hand; Prestige separately refinanced existing debt via a $400m senior notes offering around the same time
Company context: LaCorium Health (the seller/target)
Founded in 1998 in Sydney by Steven and Shelley Sher
About 26 employees